Assessment of Spondyloarthritis in an Acute Anterior Uveitis Inception Cohort: a Cross Sectional and Prospective Comparative Study of HLA-B27-positive and -negative Cases

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Spondyloarthritis (SpA) encompasses a group of inflammatory rheumatic diseases characterized by axial and/or peripheral arthritis, along with extra-articular manifestations such as enthesitis, dactylitis, uveitis, and skin lesions. Axial spondyloarthritis (axSpA), the hallmark of which is chronic sacroiliitis, can progress to vertebral fusion (bamboo spine) in advanced cases. The prevalence of axSpA varies globally, ranging from 0.1% to 1.4%, with a higher incidence in men and a typical onset in the second or third decades of life. Diagnostic approaches include imaging techniques such as sacroiliac MRI and radiographs, alongside clinical criteria like inflammatory back pain, NSAID responsiveness, peripheral arthritis, and HLA-B27 positivity. Disease management primarily involves NSAIDs, with biologics used for refractory cases, and disease activity is monitored using indices such as BASDAI and ASDAS. Acute anterior uveitis (AAU) is the most common extra-articular manifestation of SpA, particularly associated with HLA-B27 positivity. It often presents unilaterally with redness, pain, and photophobia but can lead to severe complications if inadequately treated. Around 50% of patients with HLA-B27-positive AAU have underlying SpA, and the prevalence of uveitis increases with longer disease duration. While the link between SpA and AAU is well-established, further research is needed to determine optimal systemic treatment and follow-up protocols. This study aims to assess the prevalence and clinical characteristics of SpA in patients presenting with AAU at ophthalmology clinics.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• patients with uveitis

Locations
Other Locations
Turkey
Marmara University School of Medicine
RECRUITING
Istanbul
Contact Information
Primary
Mehmet P ATAGUNDUZ, MD
pamiratagunduz@marmara.edu.tr
+90(530) 939 45 94
Backup
Şeyma ÇOLAKOĞLU-ÖZKAYA, PhD
seymacolakoglu5@gmail.com
+90(536) 519 88 60
Time Frame
Start Date: 2023-01-15
Estimated Completion Date: 2030-01-15
Participants
Target number of participants: 100
Treatments
main cohort
Related Therapeutic Areas
Sponsors
Leads: Marmara University

This content was sourced from clinicaltrials.gov